TaiGen Biopharmaceuticals Holdings Limited Long Term Debt

TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) currently reports a long-term debt of $5.8M as of June 2026. That compares with $34M in the prior-year period — down 83.0% year over year. Use the charts on this page to explore TaiGen Biopharmaceuticals Holdings Limited's long-term debt history and peer comparisons.

TaiGen Biopharmaceuticals Holdings Limited's long-term debt decreased from $34M to $5.8M — a 83.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

TaiGen Biopharmaceuticals Holdings Limited reported $5.8M in long-term debt as of June 2026. That compares with $34M in the prior-year period — down 83.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $5.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for TaiGen Biopharmaceuticals Holdings Limited, and consider following 4157.TWO for alerts when major investors trade the stock.

TaiGen Biopharmaceuticals Holdings Limited is classified in the Healthcare sector. On long-term debt, it currently shows $5.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4157.TWO with unrelated industries.